Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic

Medtronic's global medical device business has supported annual dividend raises since 1978, and it's well positioned for more growth. AbbVie's lead drug fell off a patent cliff last year, but soaring sales of recently launched treatments make the stock a buy right now.

2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

Merck

Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive healthcare players that also provide steady dividends and potential for growth. AbbVie is navigating the Humira patent cliff and expects to return to earnings growth in 2025, while Merck's Keytruda is driving sales but faces competition with a patent expiration in 2028.

AbbVie And Merck: Defensive Healthcare Plays Providing Income

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline

A key component of income investing is a portfolio that includes safe dividends, those that are unlikely to shrink or disappear.

How Safe Is AbbVie Stock's 3.7% Dividend?

Domino's Pizza

AbbVie is dealing with some near-term business headwinds, but there are several reasons (including the dividend) to like it for the long term. Domino's Pizza has a reliable business model that fuels consistent revenue and profits, and its dividend has propelled massive returns for long-term shareholders.

2 No-Brainer Dividend Stocks to Buy for the New Year

-- Expert-led symposium will explore key emerging themes in aesthetics, supported by injection session live from Allergan Aesthetics Center of Excellence in Italy -- -- New clinical data will be presented to support evolving Allergan Aesthetics portfolio -- -- 2024 marks 10 years of Allergan Medical Institute (AMI) and a decade of commitment to science and advanced education -- IRVINE, Calif. , Jan. 25, 2024 /PRNewswire/ -- Allergan Aesthetics, the industry leader in aesthetics globally, continues to bring best-in-class programming highlighting Individuality, Innovation, and Integrity at the International Master Course on Aging Science (IMCAS) World Congress 2024 in Paris from February 1-3, 2024.

Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024

American States Water

Parker-Hannifin

One of the best reasons to invest in dividend stocks is how well they hold up when the stock market falls. Whether it's a correction, a bear market, a recession, a depression or a full-on market crash, dividend-paying stocks outperform non-payers by a wide margin.

3 Dividend Stars Every Investor Should Own to Survive a Market Crash

Antero Midstream Partners

In this article, I start by explaining why I have decided to refrain from buying a fancy watch. Instead, I decided to invest in two high-yield dividend stocks. As the market valuation has turned unfavorable, I believe a shift to higher-yielding value stocks could be a smart move. Hence, in this article, I cover my strategy and two undervalued picks yielding up to 7%.

Instead Of Buying A Rolex, I'm Investing $20,000 In These 2 Stocks, Yielding Up To 7%

ALLĒ SOLIDIFIES ITS POSITIONING WITH SATISFACTION SCORES IN THE NINETY-SECOND PERCENTILE BASED ON CONSUMER SURVEY IRVINE, Calif. , Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program.

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

Johnson & Johnson

The healthcare industry is a fantastic space for investors of all ages and experience levels. Johnson & Johnson boasts a portfolio of market-leading drugs that few can rival, and it's planning out the next era of growth.

2 Genius Safe Stocks to Buy for 2024 and Beyond

Albemarle

Air Products and Chemicals

Atmos Energy

Leggett & Platt

McDonald's

NextEra Energy

Dividend Aristocrats are stocks that have been increasing dividends for the last 25 years. Inherently, these companies have deep stability and for that reason continue to be attractive.

7 Dividend Aristocrats That Will Pay You for Years to Come

Amcor Plc

Franklin Resources

Federal Realty Investment Trust

Realty Income Corp

T. Rowe Price Group

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE Ever wanted an extra set of eyes on an investment you're considering?

7 Highest Yielding Dividend Aristocrats Like AbbVie Are The Best 2024 Ideas Now

Abbott Labs

Coca-Cola

These companies have a track record of dividend growth and plan to keep that momentum going. Dividends could bolster your portfolio during tough times and multiply your winnings when the market is soaring.

My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024

Etsy

AbbVie's newer products and acquisitions should help it deal with a major patent cliff while keeping its dividend. Etsy has a solid moat and a long runway for growth despite recent troubles related to a challenging economy.

2 Beaten-Down Stocks to Buy Hand Over Fist This Year

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie's next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease. The 4R tau PET imaging biomarkers hold great promise as important new tools in advancing the understanding of neurodegenerat.

Enigma Biomedical Group - USA Signs License Agreement with AbbVie for Novel 4R Tau PET Imaging Biomarkers

ST. LOUIS--(BUSINESS WIRE)--SHARx Files Defamation and Deceptive Business Practices Suit Against AbbVie.

SHARx Files Defamation Suit Against AbbVie

In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.

AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note

Health Care Select Sector SPDR Fund

Danaher

DexCom

Eli Lilly

McKesson

UnitedHealth Group

Viatris

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.

Charts turn bullish on health-care stocks as sector takes early lead in 2024

AbbVie launched about a decade ago as Abbott's spinoff of its pharmaceuticals business. Both companies have since lifted earnings into the triple digits.

Better Growth Stock: Abbott vs. AbbVie

Altria

Northwest Natural Gas

Universal Corp

Altria owns over 10% of Anheuser-Busch InBev (NYSE: BUD), the world's largest brewer.

The 7 Highest Yielding 2024 Dividend Kings To Buy and Hold Forever

Amazon

Booking Hlds

Americans are increasingly interested in investing -- a great thing! It's important to set goals, and seeing these benchmarks can help.

Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today

American Tower

Ares Capital

Bristol-Myers

BlackRock Science & Technology

Central Securities

Chevron

Enbridge

Home Depot

Intuit

JPMorgan Equity Premium Income ETF

Barings Corporate Investors

MPLX

Morgan Stanley

Microsoft

We outline an Income Strategy for creating a self-sufficient portfolio for retirees and income-focused investors with $1 million to generate a life-long income stream. We explain the benefits of generating income through dividends and distributions rather than selling shares for capital gains. We compare the results of backtesting an income strategy with index investing for the past 24 years, starting from the year 2000.

How To Invest $1 Million In Retirement For Life-Long Income

News for AbbVie Stock (ABBV)